Breaking News Updates for the Psychedelics Industry | Page 2 of 9

Psychedelics News

Breaking News

Breaking News, Health & Wellness, Industry, Psychedelic Groundbreakers, Psychedelic Titans, Science

18 Aug 2025

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules...

By Madison Roberts

Breaking News, Industry, Press Releases, Psychedelic Groundbreakers, Science

23 Jul 2025

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

This week, Enveric announced it has received a second U.S. patent allowance for compounds in its EVM401 Series, expanding its growing intellectual property fortress. These aren’t just any molecules —...

By Madison Roberts

Breaking News, Health & Wellness, Industry, Press Releases, Psychedelic Groundbreakers, Psychedelic Titans, Science

15 Jul 2025

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Enveric Biosciences announced that its lead compound, EB-003, significantly reduced trauma-related fear behaviors in a preclinical PTSD model—highlighting its potential as a fast-acting, non-hallucinogenic treatment for a condition with few...

By Madison Roberts

Breaking News, Industry, Science

1 Jul 2025

Enveric’s EB-003 Shows Dual Mechanism Promise, Paving a New Path in Neuropsychiatric Drug Innovation

Enveric Biosciences (NASDAQ: ENVB) is quietly making a case to lead the next generation of neuropsychiatric drug innovation. On June 24, the company announced new data that could significantly broaden...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Finance, Press Releases

25 Feb 2025

Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds

Enveric Biosciences (NASDAQ: ENVB) has received its first U.S. patent for the EVM401 Series, a collection of non-hallucinogenic compounds derived from mescaline. These novel therapeutics target multiple neurological receptors associated...

By Madison Roberts

Breaking News

4 Feb 2025

A New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements

Enveric Biosciences has entered into a licensing agreement with Restoration Biologics to develop and commercialize cannabinoid-COX-2 conjugate compounds, promising a new frontier in joint disease treatment. This partnership could redefine...

By Madison Roberts

Breaking News, Industry

21 Nov 2024

MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute

After years of regulatory hurdles, MAPS has secured FDA clearance to study cannabis for PTSD in a real-world context. This groundbreaking trial focuses on veterans and aims to provide high-quality...

By Madison Roberts

Breaking News, Don’t Miss, Health & Wellness, Industry

4 Nov 2024

SoundSelf’s Wefunder Campaign: Bringing Digital Psychedelics to Mental Health Providers

SoundSelf, the groundbreaking digital therapeutics company, is launching a community investment campaign on Wefunder. This Austin-based innovator aims to revolutionize mental health care by using immersive technology to support mental...

By Madison Roberts

Breaking News, Press Releases

15 Oct 2024

Enveric Biosciences Unveils Positive Safety and Pharmacology Data for EB-003

New preclinical results showcase EB-003’s ability to target serotonergic receptors while minimizing risks of cardiovascular and CNS side effects, advancing its potential as a non-hallucinogenic treatment for mental health disorders....

By Madison Roberts

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result